SentenceIn May 2024, Takeda entered into an exclusive, worldwide option and license agreement with AC Immune for AC Immune's active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer

TAK 20-Faccession 0001395064-26-000177filed Jun 17 '26ACIU

DNLIDenali Therapeutics Inc.

SentenceTakeda paid us a $40.0 million upfront payment related to the collaboration, and an additional $110.0 million under a share purchase agreement in February 2018.

DNLI 10-Kaccession 0001714899-25-000066filed Feb 27 '25DNLI

EXELExelixis, Inc.

SentenceTo Ipsen, we granted the rights to develop and commercialize cabozantinib outside of the U.S. and Japan, and to Takeda we granted such rights in Japan.

EXEL 10-Kaccession 0000939767-26-000021filed Feb 10 '26EXEL

HCMHUTCHMED (China) Ltd

SentenceLicense and collaboration agreement with Takeda Pharmaceuticals On January 23, 2023 (as amended in June 2025), the Group and Takeda Pharmaceuticals International AG ( " Takeda " ) entered into an exclusive out-licensing agreement (the " Takeda Agreement " ) in territories outside of Mainland China, Hong Kong and Macau (the " Territory " ) to further the global development, commercialization and manufacturing of Fruzaqla, also known as fruquintinib, a targeted oncology therapy for the treatment of various types of solid tumors.

HCM 20-Faccession 0001104659-26-023822filed Mar 5 '26HCM

IPHAInnate Pharma SA

SentenceOn April 3, 2023, the Company announced that it has entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease.

IPHA 20-Faccession 0001598599-26-000005filed Apr 1 '26IPHA

KROSKeros Therapeutics

SentenceIn December 2024, Takeda entered into an exclusive licensing agreement with Keros Therapeutics to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau.

TAK 20-Faccession 0001395064-26-000177filed Jun 17 '26KROS

MESOMesoblast Ltd

SentenceWe are entitled to further payments up to €9.0 million when Takeda reaches certain product regulatory milestones.

MESO 20-Faccession 0001345099-26-000081filed Aug 27 '26MESO

NVAXNovavax Inc

SentenceUnder the Amended Takeda CLA, Takeda will continue to purchase our Matrix-M™ adjuvant to manufacture doses of finished COVID-19 Vaccine with updated adjuvant forecast and other supply terms.

NVAX 10-Kaccession 0001000694-26-000007filed Feb 26 '26NVAX

OVIDOvid Therapeutics Inc.

SentenceFor example, we co-developed soticlestat with Takeda Company Limited ("Takeda") through completion of Phase 2 clinical trials and subsequently sold our rights back to Takeda under a royalty, license and termination agreement ("RLT Agreement").

OVID 10-Kaccession 0001628280-26-019438filed Mar 18 '26OVID

PTGXProtagonist Therapeutics

SentenceIn January 2024, Takeda signed a worldwide license and collaboration agreement with Protagonist for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide of the natural hormone hepcidin, currently in a pivotal Phase 3 trial, VERIFY, for the treatment of Polycythemia Vera (PV).

TAK 20-Faccession 0001395064-26-000177filed Jun 17 '26PTGX

WVEWave Life Sciences

SentenceIn February 2018, Takeda entered into an agreement with Wave to discover, develop and commercialize nucleic acid therapies for disorders of the central nervous system (CNS).

TAK 20-Faccession 0001395064-26-000177filed Jun 17 '26WVE

—Innovent Biologicsunlisted

SentenceIn October 2025, Takeda entered into a license and collaboration agreement with Innovent for the development, manufacturing and commercialization of two late-stage investigational medicines for solid tumors, IBI363 and IBI343, worldwide outside of China, Hong Kong, Macau and Taiwan.

TAK 20-Faccession 0001395064-26-000177filed Jun 17 '26

customer

FTHFaeth Therapeutics, Inc.

SentenceWe are party to a license agreement with Takeda that was originally entered into in March 2019, or the Takeda License Agreement, between Takeda and Petra Pharma Corporation, or Petra, which was subsequently assigned by Petra to Ravenna Pharmaceuticals, Inc., or Ravenna, and later acquired by Faeth in February 2021 in connection with its acquisition of assets related to serabelisib pursuant to an asset purchase agreement with Ravenna.

FTH 10-Kaccession 0001193125-26-132014filed Mar 30 '26FTH

NBIXNeurocrine Biosciences Inc

Sentence

Order: filed share, then A–Z, unlisted last

Methodology

ties · implied moves · holdersMethod

Ties Implied moves Holders

Dependency

Sources

Methodology

ties · implied moves · holdersMethod

Ties Implied moves Holders